SGMO - Sangamo Therapeutics, Inc.
Chart Events
Price Crosses Moving Average
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 1.2500 |
| Open | 1.2400 |
| Bid | 1.2100 x 2900 |
| Ask | 1.2200 x 2200 |
| Day's Range | 1.2000 - 1.2600 |
| 52 Week Range | 1.0700 - 6.4200 |
| Volume | |
| Avg. Volume | 2,339,912 |
| Market Cap | 206.191M |
| Beta (5Y Monthly) | 1.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8200 |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.38 |
Fair Value
Related Research
Business WireSangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease
BRISBANE, Calif., May 22, 2023--SANGAMO THERAPEUTICS RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR ISARALGAGENE CIVAPARVOVEC FOR THE TREATMENT OF FABRY DISEASE
Simply Wall St.Industry Analysts Just Upgraded Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Forecasts By 52%
Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shareholders will have a reason to smile today, with the analysts making...
Business WireSangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer
BRISBANE, Calif., May 16, 2023--SANGAMO THERAPEUTICS ANNOUNCES APPOINTMENT OF LISA ROJKJAER, M.D., AS CHIEF MEDICAL OFFICER
Business WireSangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
BRISBANE, Calif., May 02, 2023--SANGAMO THERAPEUTICS TO PRESENT PRE-CLINICAL DATA FROM ITS GENOMIC ENGINEERING PLATFORM AT ASGCT
- Simply Wall St.
Analysts Just Made A Huge Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts
Celebrations may be in order for Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shareholders, with the analysts delivering...
Business WireSangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results
BRISBANE, Calif., April 26, 2023--SANGAMO THERAPEUTICS ANNOUNCES STRATEGIC UPDATE AND REPORTS PRELIMINARY FIRST QUARTER 2023 FINANCIAL RESULTS
American City Business JournalsBiogen shifts gene therapy focus as it builds $200M facility in RTP
Biogen is shifting its focus away from certain gene therapy programs as it builds out a nearly $200 million gene therapy manufacturing facility in Research Triangle Park.
ZacksStrength Seen in Pharming Group N.V. Sponsored ADR (PHAR): Can Its 5.2% Jump Turn into More Strength?
Pharming Group N.V. Sponsored ADR (PHAR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Business WireSangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast
BRISBANE, Calif., April 19, 2023--Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast
- Simply Wall St.
Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Shares Lagging The Industry But So Is The Business
You may think that with a price-to-sales (or "P/S") ratio of 2.5x Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) is...
InvestorPlace7 Sorry Pharma Stocks to Sell in April Before It’s Too Late
Finding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a company making a breakthrough in a new drug or treatment, the rewards can be extreme, but investing in pharma stocks can also mean heavy expenditures on research and testing for a drug that may not perform as well as scientists hope. Even if the drug does well, the extended regulatory process can be challenging for investors hoping for positive returns.InvestorPlace - Stock Market News, Stock Advi
American City Business JournalsThe Petri Dish: Takeda scores win from Nimbus licensing deal; Biogen exits partnership
Takeda paid Nimbus Therapeutics $4 billion for a psoriasis drug in December. It just met its primary goal in a midstage trial.
ZacksSangamo (SGMO) Loses -37.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Sangamo (SGMO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
BenzingaTwo Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo
Two big-name partners have walked away from partnerships with Sangamo Therapeutics Inc (NASDAQ: SGMO) over a few days. On Friday, the company filed an SEC document, Novartis AG (NYSE: NVS) terminated the Collaboration and License Agreement dated July 27, 2020, effective June 11, 2023. The Novartis and Sangamo were engaged in programs to research gene regulation therapies to treat three neurodevelopment disorders. Novartis has indicated to Sangamo that the termination relates to a recent strategi
ZacksSangamo (SGMO) Loses -24.09% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Sangamo (SGMO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- Simply Wall St.
In the wake of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) latest US$56m market cap drop, institutional owners may be forced to take severe actions
Key Insights Institutions' substantial holdings in Sangamo Therapeutics implies that they have significant influence...
American City Business JournalsSickle-cell gene therapy developer stops program, cuts half of staff
Gene therapy offered hope for thousands of sickle cell disease patients. Now many are ending their programs.
BenzingaSangamo Therapeutics Shares Updated Data From Fabry Gene Therapy Study, Says It Shows Evidence Of Clinical Benefit
Sangamo Therapeutics Inc (NASDAQ: SGMO) announced updated preliminary data as of October 20, 2022, the cutoff date from the Phase 1/2 STAAR study of isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for Fabry disease. As of the November 15, 2022, supplemental cutoff date, 13 patients exhibited supraphysiological levels of α-Gal A activity, sustained for over two years for the patient with the longest follow-up. All five patients who began the dose escalation pha
ZacksSangamo Therapeutics (SGMO) Reports Q4 Loss, Tops Revenue Estimates
Sangamo (SGMO) delivered earnings and revenue surprises of 11.11% and 0.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireSangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
BRISBANE, Calif., February 22, 2023--SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
Business WireSangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease
BRISBANE, Calif., February 22, 2023--Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease
ZacksHere's Why Sangamo (SGMO) is Poised for a Turnaround After Losing -17.68% in 4 Weeks
The heavy selling pressure might have exhausted for Sangamo (SGMO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Business WireSangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast
BRISBANE, Calif., February 21, 2023--SANGAMO THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 CONFERENCE CALL AND WEBCAST
ZacksSangamo Therapeutics (SGMO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Sangamo (SGMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Here's Why Sangamo (SGMO) Looks Ripe for Bottom Fishing
Sangamo (SGMO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.